These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37521859)

  • 1. Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator.
    Dong J; Zhu C; Huang Y; Li Q; Li J; Wang Z; Wang Y; Zhou Z; Sun M
    Acta Pharm Sin B; 2023 Jul; 13(7):3106-3120. PubMed ID: 37521859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.
    Chen IX; Chauhan VP; Posada J; Ng MR; Wu MW; Adstamongkonkul P; Huang P; Lindeman N; Langer R; Jain RK
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4558-4566. PubMed ID: 30700545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
    Alghamri MS; Banerjee K; Mujeeb AA; Mauser A; Taher A; Thalla R; McClellan BL; Varela ML; Stamatovic SM; Martinez-Revollar G; Andjelkovic AV; Gregory JV; Kadiyala P; Calinescu A; Jiménez JA; Apfelbaum AA; Lawlor ER; Carney S; Comba A; Faisal SM; Barissi M; Edwards MB; Appelman H; Sun Y; Gan J; Ackermann R; Schwendeman A; Candolfi M; Olin MR; Lahann J; Lowenstein PR; Castro MG
    ACS Nano; 2022 Jun; 16(6):8729-8750. PubMed ID: 35616289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
    Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
    J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
    Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
    Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice.
    Makino H; Aono Y; Azuma M; Kishi M; Yokota Y; Kinoshita K; Takezaki A; Kishi J; Kawano H; Ogawa H; Uehara H; Izumi K; Sone S; Nishioka Y
    J Med Invest; 2013; 60(1-2):127-37. PubMed ID: 23614921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J; Li R; Gao D; Chen F; Xie H
    Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
    Daniel SK; Seo YD; Pillarisetty VG
    Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury.
    Saiman Y; Jiao J; Fiel MI; Friedman SL; Aloman C; Bansal MB
    Hepatol Res; 2015 Jul; 45(7):794-803. PubMed ID: 25163538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
    Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
    Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
    Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
    Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
    Lee CH; Kakinuma T; Wang J; Zhang H; Palmer DC; Restifo NP; Hwang ST
    Mol Cancer Ther; 2006 Oct; 5(10):2592-9. PubMed ID: 17041104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer.
    Sarchio SNE; Scolyer RA; Beaugie C; McDonald D; Marsh-Wakefield F; Halliday GM; Byrne SN
    J Invest Dermatol; 2014 Apr; 134(4):1091-1100. PubMed ID: 24226205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer.
    Lu G; Qiu Y; Su X
    Eur J Pharm Sci; 2021 Feb; 157():105606. PubMed ID: 33131745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles.
    Yu Q; Tang X; Zhao W; Qiu Y; He J; Wan D; Li J; Wang X; He X; Liu Y; Li M; Zhang Z; He Q
    Acta Biomater; 2021 Oct; 133():244-256. PubMed ID: 34000465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-2 augments the therapeutic efficacy of adoptively transferred B cells which directly kill tumor cells via the CXCR4/CXCL12 and perforin pathways.
    Xia Y; Tao H; Hu Y; Chen Q; Chen X; Xia L; Zhou L; Wang Y; Bao Y; Huang S; Ren X; Lundy SK; Dai F; Li Q; Chang AE
    Oncotarget; 2016 Sep; 7(37):60461-60474. PubMed ID: 27528023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
    Liu Y; Ren CC; Yang L; Xu YM; Chen YN
    J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.